Karo Bio AB Presents Positive KB2115 Phase IIA Proof of Concept Data at Two Major Scientific Meetings

STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: KB2115 induces a profound and clinically relevant lowering of a number of risk factors for development of cardiovascular disease and was well tolerated in the first clinical phase 2 study. Key data will now be presented at two scientific meetings. The first presentation will be made later today, October 5, at the DALM (Drugs Affecting Lipid Metabolism) meeting in New York. The second presentation will be made on October 6 at the 78th Annual Meeting of the American Thyroid Association in New York.